November 5, 2007

Takeda Pharmaceutical Company Limited

Takeda's Investigational Compound TAK-442 for Treatment of Venous/Arterial
Thromboembolism Enters into Phase 2 Clinical Stage in the U.S. and Europe

Osaka, Japan, November 5, 2007 --- Takeda Pharmaceutical Company Limited (Takeda) announced today that its investigational compound TAK-442 has entered into Phase 2 clinical stage in the U.S. and Europe. TAK-442 is a novel Factor Xa inhibitor discovered and created by Takeda.

TAK-442 is an oral selective and direct competitive inhibitor of activated Factor X (FXa). As Factor Xa plays a critical role in the blood coagulation cascade, inhibition of FXa is expected to result in interruption of either venous or arterial thromboembolism, such as pulmonary embolism, cerebral infarction, etc.

"We are pleased with the progress of TAK-442's development stage into Phase 2 since this compound is expected to enhance our franchise of lifestyle-related diseases, which is one of four core therapeutic areas, such as cardiovascular and metabolic diseases including diabetes," said Masaomi Miyamoto, Ph.D., General Manager of Pharmaceutical Development Division of Takeda. "We will vigorously conduct development activities in order to bring this novel treatment option to the patients as early as possible.”

About Takeda

Located in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products. Additional information about Takeda is available through its corporate website, www.takeda.com.

# # #